- Full-Year Forecasts:
- Operating income forecast: 43.20 billion yen (previously saw 43.00 billion yen, estimated 45.37 billion yen)
- Net income forecast: 32.20 billion yen (previously saw 32.00 billion yen, estimated 34.29 billion yen)
- Net sales forecast: 320.00 billion yen (previously saw 300.00 billion yen, estimated 303.75 billion yen)
- Dividend forecast: 33.00 yen (previously saw 30.00 yen, estimated 30.25 yen)
- First Quarter Results:
- Operating income: 11.79 billion yen, up 4.4% year-over-year (estimated 12.46 billion yen)
- Net income: 8.48 billion yen, down 6.7% year-over-year (estimated 9.2 billion yen from 2 estimates)
- Net sales: 68.36 billion yen, up 12% year-over-year (estimated 67.66 billion yen)
- Analyst Ratings:
- 10 buy ratings
- 0 hold ratings
- 0 sell ratings
- Past Results:
- Comparisons based on the company’s original disclosures
A look at Rohto Pharmaceutical Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Rohto Pharmaceutical Co., Ltd. has been assessed using Smartkarma Smart Scores, with a notable Growth score of 4 and a Resilience score of 4, indicating a positive long-term outlook. The company’s strong momentum score of 5 further reinforces this optimistic outlook. Rohto Pharmaceutical, known for manufacturing pharmaceuticals, cosmetics, eyewash, bath soaps, and more, seems well-positioned for growth and shows resilience in the face of challenges. With a balanced Value and Dividend score of 2 each, Rohto Pharmaceutical demonstrates stability and potential for future development.
Overall, considering the Growth, Resilience, and Momentum scores, Rohto Pharmaceutical appears primed for sustained growth and success in the long term. The company’s diversified product portfolio, including contact lenses and health foods, coupled with its strong partnership with Mentholatum (US), adds further strength to its position in the market. Investors and stakeholders may find Rohto Pharmaceutical an attractive opportunity for investment based on its favorable Smartkarma Smart Scores across key factors affecting its future performance.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
